---

Principal Investigator

Alvaro Aytes, Ph.D.
Group Leader,  Department of Molecular Mechanisms and Experimental Therapies in Oncology, IDIBELL
Principal Investigator, Program Against Cancer Therapeutic Resistance (ProCURE) IDIBELL and ICO joint initiative
Member, Prostate Cancer Functional Unit, Hospital Universitari de Bellvitge

I obatained my Ph.D. in Cell Biology and Pathology from Universtiy of Barcelona in 2008 and in 2009 I joined the laboratory of Dr. Abate-Shen as a postdoctoral fellow at Columbia University (New York) working on developing genetically-engineered mouse models and computational approaches to uncover acctionable driver mechanisms in prostate cancer. In 2015 I was recruited as faculty at the joint initiative from IDIBELL and the Catalan Institute of Oncology to launch the Program Against Cancer Therapeutic Resistance.

Lab members

Katia Ruggero
Postdoctoral Research Scientist
Ph.D. University of Padua, Italy

I obtained my Ph.D in 2012 at the University of Padua, where I studied the role of microRNAs in oncogenic transformation driven by human T-cell leukemia virus type 1. In 2013 I join the laboratory of Prof. Rabbitts as a postdoctoral fellow at the WIMM in Oxford, workning on mechanisms of oncogenesis in LMO2-directed T cell leukaemia. In 2016 I joined Dr. Aytes laboratory to carry out reaserch on the role of epigenetic mechanisms of therapeutic resistance in prostate cancer.

Sònia Farran Matas
Ph.D. candidate
B.S. MSs

Sonia´s Master´s thesis focuses on dissecting the cell cycle independent functions of the master regulators FOXM1 and CENPF, with a particular interest in epigentically controlled oncogen activation. While she continues that line of research she is also focusing on the role PARPi in HDR proficient prostate cancer tumors.

Former Lab members

Maialen de la Cuesta Etxeberria

Alba Calvet Pavon